NCT01304784 - A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

June 30, 2014

Conditions

HER-2 Gene Amplification

Interventions

DRUG

Cisplatin, Capecitabine, Trastuzumab and MM-111

Conventional chemotherapy

DRUG

Lapatinib +/- Trastuzumab and MM-111

Conventional chemotherapy

DRUG

Paclitaxel, Trastuzumab and MM-111

Conventional chemotherapy

DRUG

Lapatinib, trastuzumab, paclitaxel, and MM-111

Conventional chemo

DRUG

Docetaxel, trastuzumab and MM-111

Conventional chemotherapy

Trial Locations (15)

12206

New York Oncology/Hematology, Albany

19111

Fox Chase Cancer Center, Philadelphia

23502

Virginia Oncology Associates, Norfolk

29605

GHS Institute of Transitional Oncology Research, Greenville

30342

Georgia Cancer Specialists, Atlanta

45429

Innovation Center - Kettering Medical Center Health Network, Kettering

46151

Central Indiana Cancer Centers, Indianapolis

47908

Horizon Oncology Research, Inc, Lafayette

75246

Texas Oncology PA North/Sammans Cancer Center, Dallas

75702

Texas Oncology - Tyler, Tyler

78731

Texas Oncology Cancer Center, Austin

80218

Rocky Mountain Cancer Centers, Denver

89135

Comprehensive Cancer Centers of Nevada, Las Vegas

98684

Northwest Cancer Specialists-Vancouver Cancer Center, Vancouver

99218

Evergreen Hematology and Oncology, Spokane